Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Earnings Report - Johnson & Johnson is set to release its fourth-quarter earnings on January 21, with analysts expecting earnings of $2.47 per share, an increase from $2.04 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $24.16 billion, up from $22.52 billion reported last year [1] Clinical Study Update - On January 14, Johnson & Johnson shared topline results from the Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy for multiple myeloma, a type of blood cancer [2] - Following this news, shares of Johnson & Johnson fell by 0.2%, closing at $218.21 [2] Analyst Ratings - Bernstein analyst Lee Hambright maintained a Market Perform rating and raised the price target from $193 to $208 [4] - Barclays analyst Matt Miksic maintained an Equal-Weight rating and raised the price target from $197 to $217 [4] - Goldman Sachs analyst Asad Haider maintained a Buy rating and increased the price target from $213 to $240 [4] - B of A Securities analyst Tim Anderson maintained a Neutral rating and raised the price target from $204 to $220 [4] - Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $190 to $197 [4]